Amylin's loss for 4th-qtr 2007 worsens 32%
Higher marketing costs associated with the diabetes drugs Byetta (exenatide) and Symlin (pramlintide acetate), led to increased fourth-quarter 2007 losses at US drugmaker Amlyin Pharmaceuticals. The San Diego-headquartered firm reported a deficit of $76.9 million, or $0.57 per share, for the three months ended December 31, 2007, down a further 31.7% from the shortfall it recorded in the comparable period in 2006. Analysts polled by Thomson Financial had predicted a loss of $0.44 per share on revenues of $202.6 million.
36% sales hike still disappoints
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze